[PDF][PDF] Randomized, double-blind, placebo-controlled trial of erythropoietin in non–small-cell lung cancer with disease-related anemia
JR Wright, YC Ung, JA Julian, KI Pritchard… - Journal of Clinical …, 2007 - researchgate.net
JR Wright, YC Ung, JA Julian, KI Pritchard, TJ Whelan, C Smith, B Szechtman, W Roa…
Journal of Clinical Oncology, 2007•researchgate.netPurpose Previous trials have suggested a quality-of-life (QOL) improvement for anemic
cancer patients treated with erythropoietin, but few used QOL as the primary outcome. We
designed a trial to investigate the effects of epoetin alfa therapy on the QOL of anemic
patients with advanced non–small-cell carcinoma of the lung (NSCLC).
cancer patients treated with erythropoietin, but few used QOL as the primary outcome. We
designed a trial to investigate the effects of epoetin alfa therapy on the QOL of anemic
patients with advanced non–small-cell carcinoma of the lung (NSCLC).
Purpose
Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome. We designed a trial to investigate the effects of epoetin alfa therapy on the QOL of anemic patients with advanced non–small-cell carcinoma of the lung (NSCLC).
researchgate.net